Jacob Gottlieb, Altium Capital Founder, Excited About The Next Big Things In Medicine And About The Companies Finding Them
Advanced stage cancer patients often undergo chemotherapy or radiation therapy. Under these treatments its not unusual for them to fall prey to a host of side effects, one such being mucositis. Mucous membranes, from the mouth on down, ulcerate and inflame. The condition is devastatingly painful and makes eating difficult, besides opening the body up to a host of infections. The physician-founded probiotic and antibiotic company, Oragenics, is at the helm of developing a biotherapeutic approach to mucositis.
Where, one might ask, does a company seeking a cure for mucositis find investment capital? At the same place as Oramed, a company which develops new systems for the oral delivery of drugs, finds investment capital. Also, at the same place where Aramin, which exploits the potential of lipid science to create new interventions for cardiovascular disease, finds investment capital. They all find it at Altium Capital.
Created in 2018, Altium Capital is the brainchild of Jacob Gottlieb. A first rate financier, Gottlieb got his chops at Balyasny Asset Management, prospering as a portfolio manager at a company known for generating absolute returns. From there, he went on to create his own hedge fund, Visium. Yet, long before Altium Capital and Balyasny Asset Management, Jacob Gottlieb was already an aficionado of all things medical and innovative. In fact, Jacob Gottlieb attained a medical degree at New York University, besides garnering a BA, magna cum laude, from Brown University in Economics.
In the end, finance won out as the primary life-path of Jacob Gottlieb. But, he never stopped caring about patients. Moreover, he never stopped being excited about medicine and where it’s going. Hence, Altium Capital, dedicated to finding companies with the same zeal for medicine and the same eagerness to find that next big thing that will make patients lives better.